Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) — StellaPhase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(15 sites)
China
Beijing Cancer Hospital, Beijing, Beijing Municipality Chongqing Cancer Hospital, Chongqing, Chongqing Municipality Fujian Medical University Union Hospital, Fuzhou, Fujian Guangdong Academy of Medical Sciences Guangdong Provincial People's Hospital, Guangzhou, Guangdong Sun Yat-sen University Cancer Center, Guangdong, Guangzhou Affiliated Hospital of Nantong University, Nantong, Jiangsu Northern Jiangsu People's Hospital, Yangzhou, Jiangsu The First Hospital of China Medical University, Shenyang, Liaoning Liaoning Cancer Hospital & Institute, Shenyang, Liaoning Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, Shanghai Municipality Shanghai First Maternity and Infant Hospital, Shanghai, Shanghai Municipality The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an, Shanxi West China Hospital of Sichuan University, Chengdu, Sichuan Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang Last updated February 2024